{"commentary":{"count":9,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":4,"podcast":4,"x_thread":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04116502\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"MITHRIDATE","nct_id":"NCT04116502","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=mithridate-nct04116502. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"MITHRIDATE","arms":[{"description":"Treatment with Ruxolitinib","label":"A- Ruxolitinib","type":"EXPERIMENTAL"},{"description":"Best Available Therapy (BAT), Treatment with hydroxycarbamide OR Interferon A","label":"B- Hydroxycarbamide OR Interferon A","type":"ACTIVE_COMPARATOR"}],"collaborators":["Novartis","MPN Voice","National Cancer Institute, France"],"completion_date":{"date":"2030-04-01","type":"ESTIMATED"},"conditions":["Polycythemia Vera"],"enrollment":{"count":586,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Ruxolitinib","type":"DRUG"},{"name":"Hydroxycarbamide","type":"DRUG"},{"name":"Interferon-Alpha","type":"DRUG"}],"last_update":"2026-04-28","lead_sponsor":"University of Birmingham","official_title":"A Phase III, Randomised, Open-label, Multicenter International Trial Comparing Ruxolitinib With Either HydRoxycarbamIDe or Interferon Alpha as First Line ThErapy for High Risk Polycythemia Vera","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2028-10-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Event Free Survival (EFS)","timeFrame":"the time from randomisation to the date of the first major thrombosis/haemorrhage, death,transformation to Myelodysplastic Syndromes, Acute Myeloid Leukaemia or Post-polycythemia Vera Myelofibrosis, if within the ~3 year trial period"}],"references":[],"start_date":{"date":"2019-10-25","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera","url":"https://clinicaltrials.gov/study/NCT04116502"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/mithridate-nct04116502"}